Amit Kumar Buys 3,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, July 24th. The shares were acquired at an average price of $3.73 per share, with a total value of $11,190.00. Following the acquisition, the chief executive officer owned 643,812 shares in the company, valued at $2,401,418.76. This trade represents a 0.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Monday, July 20th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar bought 3,188 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Trading Down 1.1%

NASDAQ ANIX opened at $3.48 on Thursday. The stock has a market cap of $118.39 million, a PE ratio of -11.23 and a beta of 0.59. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46. The company’s 50-day moving average price is $2.94 and its 200-day moving average price is $2.92.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. As a group, sell-side analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new position in Anixa Biosciences during the fourth quarter valued at approximately $83,000. Graham Capital Management L.P. purchased a new stake in Anixa Biosciences during the fourth quarter worth $81,000. CIBC Bancorp USA Inc. bought a new stake in Anixa Biosciences during the 3rd quarter valued at $51,000. Marshall Wace LLP bought a new stake in Anixa Biosciences during the 2nd quarter valued at $39,000. Finally, Millennium Management LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter valued at $38,000. 29.13% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on ANIX shares. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Zacks Research upgraded Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Anixa Biosciences has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.